Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab.

Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab.

The current pandemic emergence of novel coronavirus disease (COVID-19) poses a relevant threat to global health. SARS-CoV-2 infection is characterized by a wide range of clinical manifestations, ranging from absence of symptoms to severe forms that need intensive care treatment. Here, plasma-EDTA sa...

Full description

Bibliographic Details
Main Authors: Gaia Meoni, Veronica Ghini, Laura Maggi, Alessia Vignoli, Alessio Mazzoni, Lorenzo Salvati, Manuela Capone, Anna Vanni, Leonardo Tenori, Paolo Fontanari, Federico Lavorini, Adriano Peris, Alessandro Bartoloni, Francesco Liotta, Lorenzo Cosmi, Claudio Luchinat, Francesco Annunziato, Paola Turano
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-02-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1009243

Internet

https://doi.org/10.1371/journal.ppat.1009243

Similar Items